



CODEN [USA]: IAJPBB

ISSN : 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

SJIF Impact Factor: 7.187

<http://doi.org/10.5281/zenodo.4284642>Available online at: <http://www.iajps.com>

Research Article

THE ANALYSIS OF THE PROGNOSTIC INCENTIVE AMONG DAYTIME AND EVENING SYSTOLIC BLOOD PRESSURE ON RENAL OUTCOMES

¹Dr Aleena Farooq, ²Dr Muhammad Aamir Javed, ³Dr Adiya Hameed

¹House Officer, the University of Lahore Teaching Hospital

²Jinnah Hospital Lahore

³DHQ Teaching Hospital Sargodha

Article Received: August 2020

Accepted: September 2020

Published: October 2020

Abstract:

Aim: Contrasts in the prescient estimation of daytime systolic circulatory strain (SBP) and evening SBP by wandering blood pressure observing on renal results have not been completely explored in persistent kidney sickness patients. This investigation analyzed the prognostic incentive among daytime and evening SBP on renal results in CKD.

Methods and Results: 428 patients were interested in this upcoming retrospective study. End-phase renal illness (ESRD) or mortality was the composite renal endpoint. Our current research was conducted at Lahore General Hospital, Lahore from March 2019 to February 2020. Cox models have been used to assess the daytime and night time association SBP with renal outcomes. 150 kidney functions were present (ESRD, 136; destruction, 23). Multivariable Cox tests found that the peril proportions (PDPs) [95 percent stretch (CI)] were 1.16 (1.03–1.27) ($P=0.03$) and 1.16 (1.056–1.28) ($P<0.02$) for each 10-mmHg rise during the day and evening. The SBP quartile was also compared to SBP (95 percent) and SBP quartile (0.70–0.25), 1.09 (0.61–1.94) and 1.58 (0.88–2.85; $P=0.13$; trend=0.17; SSB (0.62–1.97), 1:32 (0.75–2.29) and 1.83 (1.01–3.32; trend=0.047) (P) and SBP (0.047), each individual quartile in contrast, for the first day and/or evening time. ($P=0.047$)

Conclusion: Night-time SBP seemed better than daytime SBP for anticipating renal results in this populace of patients.

Keywords: Prognostic Incentive, Daytime, Evening, SBP, CKD.

Corresponding author:**Dr. Aleena Farooq,**

House Officer, the University of Lahore Teaching Hospital

QR code




Please cite this article in press Aleena Farooq et al, *The Analysis Of The Prognostic Incentive Among Daytime And Evening Systolic Blood Pressure On Renal Outcomes* ., *Indo Am. J. P. Sci*, 2020; 07(10).

INTRODUCTION:

The chance of coronary function and decrease and the danger increases with development of the stage of chronic kidney disease is increased. CKD is known to be a critical general medical concern, and hypertension (BP) contributes to the movement of renal infections [1]. In the administration of CKD patients, hypertension treatment also became the primary mediation. BP inspections are necessary for the analysis of the danger of cardiovascular and renal functions and death in this unusual situation [2]. Walking pulse control is useful to reliably detect hypertension and also gives meaningful results, such as plunging status and BP non-compliance correlated with target organ damage that cannot be captured with center BP readings [3]. Indicators of cardiovascular activity and decline of the general population and hypertensive subjects have been taken into account for the components obtained from ABPM. In comparison, it has been shown that ABPM predicts both triggers and coronary passages in high blood pressure patients even better than BP facilities [4]. In CKD patients, ABPM is known to be a safer device to predict cardiovascular risks, movement of CKDs, end phase renal disease (ESRD) and demise thought of BP on the basis of an office.12 Certain exams have tended to the association of sections of ABPM with results of CKD patients. Amongst the ABPM elements, BP offers more practical prognostic evidence than BP during the day in hypertensive patients, while BP evening was found to be greater than BP during the day when the general populace expects CKD. Stylist BP night time is a superior predictor of cardiovascular activity in hypertensive patients in particular [5].

METHODOLOGY:

The current overview of the patient enrolment steps is shown in Figure 1: 630 continuous CKD patients have

Figure 1:

been enrolled into the Kyushu Clinical Center National Hospital Organization for the diagnosis and guidance of CKD from June 2009 to May 2016. Figure 2. Our current research was conducted at Lahore General Hospital, Lahore from March 2019 to February 2020. The norm (n=34) or no usable ABPM data (n=54) is barred from patients that had any damage (n=58), intensive intensification of CKDs (n = 15), glomerular filtration rate (eGFR), or standard (n=8 mL / mon/1.74 m²). In this proposed observational examination, more than 486 patients were chosen. Both the patients were discharged live from the clinic and were not backed up with dialysis at the clinic. Of these 487 patients, an further 61 were refused within a half year of release. Finally, we dissected 426 patients. Until December 2016, information was stored. Both patients agreed to the convention which was approved by the Lahore General Hospital Ethics Committee. All the patients were educated. ESRD has been identified as involving hemodialysis or peritoneal dialysis, and ESRD time was the benchmark term for the day the first meeting of dialysis was held. The pass was identified as arriving at ESRD beforehand. Data on passages were collected from the emergency examination clinic records for hospital patients who kicked buckets and from the different foundations of patients who understood buckets in numerous health clinics. During more than half a year of their continued care they were performed in patients who had lost their production (n=69) or had started promoting dialysis for the intensive composition of kidney work induced by congestive coronary decay or irresistible illnesses (n=6). The medium time after this time was 18.7 months (with full scope 7.3 to 67.6 months) for those 76 monitored patients.

Table 1:

According to Quartiles of Daytime SBP					
Variable	Daytime SBP level				P value
	94–119 mmHg (n=107)	120–131 mmHg (n=108)	132–143 mmHg (n=106)	144–188 mmHg (n=100)	
Age (years)	65.3 (48.8–74.9)	67.8 (60.5–75.8)	72.5 (61.1–78.7)	71.5 (62.2–79.3)	<0.01
Male, n (%)	56 (52)	80 (74)	71 (67)	74 (74)	<0.01
Diabetes mellitus, n (%)	30 (28)	42 (39)	45 (42)	60 (60)	<0.01
Hypertension, n (%)	68 (64)	88 (81)	96 (91)	99 (99)	<0.01
Smoking, n (%)	48 (45)	57 (53)	59 (56)	62 (62)	0.10
Dyslipidemia, n (%)	71 (66)	76 (70)	81 (76)	74 (74)	0.39
Ischemic heart disease, n (%)	11 (10)	21 (19)	23 (22)	21 (21)	0.11
Body mass index (kg/m ²)	22.7 (20.4–25.7)	22.7 (20.5–25.5)	22.2 (20.5–25.6)	22.2 (20.9–24.7)	0.99
Daily proteinuria (g/day)	0.43 (0.14–1.09)	0.90 (0.23–1.75)	1.43 (0.45–3.24)	2.29 (0.82–5.46)	<0.01
Hemoglobin (g/dL)	11.7 (10.3–13.1)	11.0 (10.0–12.9)	10.2 (9.0–12.1)	9.6 (8.5–11.1)	<0.01
eGFR (mL/min/1.73m ²)	40.1 (25.8–63.9)	27.1 (17.2–45.8)	23.7 (15.5–35.5)	17.6 (12.8–30.8)	<0.01
Serum albumin (g/dL)	3.7 (3.4–3.9)	3.6 (3.2–3.8)	3.4 (3.0–3.7)	3.1 (2.5–3.6)	<0.01
Serum phosphorus (mg/dL)	3.6 (3.1–4.0)	3.5 (3.2–4.0)	3.8 (3.4–4.2)	3.8 (3.4–4.2)	<0.01
24-h SBP (mmHg)	109 (103–115)	124 (120–128)	136 (133–140)	156 (148–163)	<0.01
24-h DBP (mmHg)	66 (62–71)	73 (67–79)	78 (73–84)	85 (76–91)	<0.01
Daytime SBP (mmHg)	110 (106–115)	126 (123–129)	137 (134–140)	158 (150–164)	<0.01
Daytime DBP (mmHg)	68±7	74±9	80±9	85±12	<0.01
Night-time SBP (mmHg)	106 (96–115)	121 (113–129)	134 (127–142)	152 (140–164)	<0.01
Night-time DBP (mmHg)	64 (59–70)	70 (63–76)	76 (69–81)	80 (72–88)	<0.01
Night-to-day ratio of SBP	0.96 (0.91–1.03)	0.96 (0.91–1.00)	0.97 (0.93–1.03)	0.95 (0.90–1.02)	0.38
Dipper, n (%)	21 (20)	23 (21)	13 (12)	22 (22)	0.25
Non-dipper, n (%)	51 (48)	56 (52)	54 (51)	41 (41)	0.40
Extreme dipper, n (%)	2 (2)	2 (2)	0 (0)	2 (2)	0.56
Riser, n (%)	33 (31)	27 (25)	39 (37)	35 (35)	0.26
Non-dipping, n (%) ^a	84 (79)	83 (77)	93 (88)	76 (76)	0.13
Antihypertensive drugs, n (%)	71 (66)	83 (77)	92 (87)	96 (96)	<0.01
Antihypertensive drugs only in the daytime, n (%)	47 (44)	41 (38)	45 (42)	37 (37)	0.69
Antihypertensive drugs only at night, n (%)	3 (3)	3 (3)	2 (2)	2 (2)	0.95
Antihypertensive drugs in both the daytime and at night, n (%)	21 (20)	39 (36)	45 (42)	57 (57)	<0.01
RAAS inhibitors, n (%)	60 (56)	69 (64)	70 (66)	79 (79)	<0.01
CCB, n (%)	42 (39)	63 (58)	84 (79)	85 (85)	<0.01
α-blocker, n (%)	2 (2)	11 (10)	10 (9)	19 (19)	<0.01
β-blocker, n (%)	13 (12)	20 (19)	22 (21)	20 (20)	0.34
Diuretics, n (%)	28 (26)	30 (28)	33 (31)	47 (47)	<0.01

Values are expressed as mean±SD, number (%) or median (interquartile range). ^aNon-dipping, non-dipper+riser. ABPM, ambulatory blood pressure monitoring; CCB, calcium-channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure.

RESULTS:

The average age was 71.6 years (full scope, 21 to 92 years) in the 425 patients (283 men and 142 dames). The middle eGFR was 27.5 mL / min/1.74 m² for all participants (complete reach: 9.2 – 121.4 mL / min/1.74 m²). Of the 425 patients, 69 patients (17.3%), 119 (28.9%), 142 (33.7%) and 94 (22.3%) were listed separately in the CKD phases 1–2, 3, 4 and 5. Constant glomerulonephritis (30%), 126 patients, hypertensive nephrosclerosis (29.0%), Diabetic nephropathy (25%, 107 patients, 14.5%, 58 patients),

and Obscuro (2.4%, 10 patients) is important causes for renal failure. The incidence was 177 (42 percent), 351 (84 percent), 228 (56 percent), 304 (73 percent), and 77 (19 percent), respectively.). Diabetes, diabetes mellitus, elevated blood sugar levels were also recorded as having a disorder. The median figures for the SBP for all the participants of day and evening were 131 mmHg and 127 mmHg (interquartile range 113–143). The commonness of each plunging status was: scoop, 79 (19%); non-scoop, 202 (49%); extraordinary scoop, 7 (2%); and riser, 136 (33%), and

the pervasiveness of patients with non-plunging was high (84%). The quantity of patients treated with antihypertensive drugs was 347 (82%); utilization of antihypertensive medications just in the daytime, 170; just around evening time, 10; and in both the daytime and around evening time, 162. Renin-angiotensin-aldosterone framework inhibitors, calcium-channel blockers, α -blockers, β -blockers, and diuretics were

directed in 278, 274, 42, 75, and 138 patients, individually. Table 1 and Table 2 show the clinical boundaries agreeing to quartiles of daytime and evening time SBP, separately. As both daytime and evening time SBP levels expanded, the pervasiveness of male sex, diabetes mellitus, and hypertension fundamentally expanded.

Table 2:

According to Quartiles of Night-Time SBP					
Variable	Night-time SBP level				P value
	84–113 mmHg (n=110)	114–127 mmHg (n=104)	128–141 mmHg (n=103)	142–194 mmHg (n=104)	
Age (years)	64.5 (47.7–74.4)	70.2 (61.0–75.9)	69.3 (60.4–78.6)	72.6 (62.3–79.8)	<0.01
Male, n (%)	60 (55)	69 (66)	78 (76)	74 (71)	<0.01
Diabetes mellitus, n (%)	24 (22)	39 (38)	43 (42)	71 (68)	<0.01
Hypertension, n (%)	66 (60)	86 (83)	97 (94)	102 (98)	<0.01
Smoking, n (%)	42 (38)	58 (56)	57 (55)	69 (66)	<0.01
Dyslipidemia, n (%)	72 (65)	75 (72)	85 (83)	70 (67)	0.03
Ischemic heart disease, n (%)	9 (8)	20 (19)	27 (26)	20 (19)	<0.01
Body mass index (kg/m ²)	22.6 (20.2–25.4)	22.8 (21.1–25.9)	22.2 (20.3–25.8)	22.2 (20.2–24.6)	0.29
Daily proteinuria (g/day)	0.44 (0.15–1.10)	0.78 (0.20–2.03)	1.15 (0.45–2.86)	2.54 (0.94–4.99)	<0.01
Hemoglobin (g/dL)	11.7 (10.4–13.4)	11.2 (9.9–12.8)	10.2 (8.9–12.3)	9.6 (8.8–11.0)	<0.01
eGFR (mL/min/1.73m ²)	38.7 (21.8–63.9)	32.1 (17.1–56.0)	22.1 (14.7–34.3)	19.7 (13.0–30.5)	<0.01
Serum albumin (g/dL)	3.7 (3.4–3.9)	3.6 (3.3–3.8)	3.5 (3.1–3.7)	3.0 (2.4–3.4)	<0.01
Serum phosphorus (mg/dL)	3.5 (3.1–4.0)	3.6 (3.3–4.0)	3.9 (3.4–4.2)	3.7 (3.4–4.2)	<0.01
24-h SBP (mmHg)	110 (103–116)	124 (120–128)	137 (133–142)	155 (144–163)	<0.01
24-h DBP (mmHg)	66 (61–72)	74 (67–79)	79 (71–84)	82 (75–89)	<0.01
Daytime SBP (mmHg)	112 (107–121)	126 (119–132)	138 (132–145)	154 (141–163)	<0.01
Daytime DBP (mmHg)	69±8	75±9	80±11	83±12	<0.01
Night-time SBP (mmHg)	104 (97–109)	121 (118–124)	134 (131–138)	152 (147–164)	<0.01
Night-time DBP (mmHg)	63 (56–68)	71 (66–76)	76 (68–82)	81 (74–88)	<0.01
Night-to-day ratio of SBP	0.91 (0.85–0.96)	0.96 (0.92–1.00)	0.98 (0.93–1.02)	1.03 (0.97–1.07)	<0.01
Dipper, n (%)	44 (40)	13 (13)	16 (16)	6 (6)	<0.01
Non-dipper, n (%)	52 (47)	66 (63)	54 (52)	30 (29)	<0.01
Extreme dipper, n (%)	5 (5)	0 (0)	1 (1)	0 (0)	0.01
Riser, n (%)	9 (8)	25 (24)	32 (31)	68 (65)	<0.01
Non-dipping, n (%) ^a	61 (55)	91 (88)	86 (84)	98 (94)	<0.01
Antihypertensive drugs, n (%)	70 (64)	82 (79)	92 (89)	98 (94)	<0.01
Antihypertensive drugs only in the daytime, n (%)	46 (42)	41 (39)	41 (40)	42 (40)	0.99
Antihypertensive drugs only at night, n (%)	5 (5)	2 (2)	2 (2)	1 (1)	0.35
Antihypertensive drugs in both the daytime and at night, n (%)	19 (17)	39 (38)	49 (48)	55 (53)	<0.01
RAAS inhibitors, n (%)	60 (55)	64 (62)	71 (69)	83 (80)	<0.01
CCB, n (%)	39 (35)	68 (65)	81 (79)	86 (83)	<0.01
α -blocker, n (%)	2 (2)	8 (8)	12 (12)	20 (19)	<0.01
β -blocker, n (%)	15 (14)	19 (18)	23 (22)	18 (17)	0.43
Diuretics, n (%)	25 (23)	32 (31)	37 (36)	44 (42)	0.02

Values are expressed as mean±SD, number (%) or median (interquartile range). ^aNon-dipping, non-dipper+riser. Abbreviations as in Table 1.

Table 3:

	Model 1				Model 2			
	HR	95% CI	P value	P for trend	HR	95% CI	P value	P for trend
Daytime SBP (every 10-mmHg increase)	1.37	1.26–1.49	<0.01	–	1.13	1.02–1.26	0.02	–
Daytime SBP				<0.01				0.16
Q1 (n=107, 94–119 mmHg)		(Ref.)				(Ref.)		
Q2 (n=108, 120–131 mmHg)	1.78	1.02–3.10	0.04		1.25	0.70–2.25	0.45	
Q3 (n=106, 132–143 mmHg)	2.81	1.63–4.85	<0.01		1.09	0.61–1.94	0.77	
Q4 (n=100, 144–188 mmHg)	4.95	2.93–8.35	<0.01		1.58	0.88–2.85	0.13	
Night-time SBP (every 10-mmHg increase)	1.28	1.20–1.37	<0.01	–	1.15	1.05–1.27	<0.01	–
Night-time SBP				<0.01				0.03
Q1 (n=110, 84–113 mmHg)		(Ref.)				(Ref.)		
Q2 (n=104, 114–127 mmHg)	1.46	0.83–2.58	0.19		1.09	0.61–1.96	0.78	
Q3 (n=103, 128–141 mmHg)	2.75	1.63–4.66	<0.01		1.31	0.76–2.28	0.33	
Q4 (n=104, 142–194 mmHg)	5.19	3.13–8.60	<0.01		1.82	1.00–3.30	0.049	
Daytime DBP (every 10-mmHg increase)	1.19	1.02–1.38	0.03	–	1.18	0.996–1.39	0.06	–
Daytime DBP				<0.01				0.08
Q1 (n=118, 44–69 mmHg)		(Ref.)				(Ref.)		
Q2 (n=95, 70–76 mmHg)	1.07	0.67–1.70	0.78		1.61	0.98–2.65	0.06	
Q3 (n=113, 77–84 mmHg)	1.18	0.76–1.83	0.46		1.12	0.69–1.81	0.65	
Q4 (n=95, 85–114 mmHg)	2.08	1.31–3.29	<0.01		1.97	1.13–3.45	0.02	
Night-time DBP (every 10-mmHg increase)	1.25	1.09–1.44	<0.01	–	1.20	1.02–1.42	0.03	–
Night-time DBP				<0.01				0.04
Q1 (n=111, 39–64 mmHg)		(Ref.)				(Ref.)		
Q2 (n=103, 65–71 mmHg)	1.54	0.97–2.46	0.07		1.70	1.03–2.80	0.04	
Q3 (n=103, 72–79 mmHg)	1.98	1.25–3.16	<0.01		1.50	0.90–2.51	0.12	
Q4 (n=104, 80–112 mmHg)	2.12	1.31–3.44	<0.01		1.89	1.10–3.26	0.02	
Night-to-day ratio of SBP				0.07				0.21
Q1 (n=107, 0.66–0.91)		(Ref.)				(Ref.)		
Q2 (n=104, 0.91–0.96)	1.59	0.98–2.58	0.06		1.48	0.89–2.47	0.13	
Q3 (n=105, 0.96–1.03)	1.37	0.86–2.18	0.19		1.46	0.89–2.38	0.13	
Q4 (n=105, 1.03–1.27)	1.62	1.02–2.56	0.04		1.40	0.85–2.31	0.19	
Non-dipping^a (vs. Dipping^b)	1.43	0.93–2.18	0.10	–	1.29	0.83–2.02	0.26	–

Model 1: adjusted for age and sex. Model 2: model 1 plus adjusted for diabetes mellitus, smoking, dyslipidemia, ischemic heart disease, use of immunosuppressants, use of RAAS inhibitors, use of antihypertensive drugs only in the daytime, only at night or use in both the daytime and at night, body mass index, daily proteinuria, hemoglobin, eGFR, serum phosphorus, and serum albumin. ^aNon-dipping, non-dipper+riser; ^bDipping, dipper+extreme dipper. CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1.

DISCUSSION:

This thesis examined the free association of SBP daytime and night with composite renal results and examined the precious predictions of these two parameters on adverse renal results [6]. The separation and comparison in the evening of SBP in quartiles and the first quartile (allows to 1116 mmHg) resulted in the overall chance of composite renal outcomes being raised in patients in the fourth quartile (allows for 142 mmHg) [7]. In the fourth quartile, patients with SBP daily level of > 146 mmHg reported an elevated chance of 59 percent and patients with SBP daily rate of > 117 mmhg had no content at all, however [8]. Previous studies have demonstrated that BP has a stronger incentive to cardiovascular and renal functions at night and that BP in hypertensive patients as well as those who have CKDs is in comparison and

daytime. BP was considered to be a better predictor for improving CCD in the all-inclusive culture in the night [9]. In the present analysis, SBP in the evening was also observed to prevail for daytime SBP-composite renal effects. There was no clear clarity as to whether BP had a more substantiated incentive for antagonistic outcomes and BP during the day. Any analytical systems have been suggested as to how evening BP impacts an impotent guess [10].

CONCLUSION:

This test tested whether the ESRD or moving composite endpoint was correlated with daytime or evening SBP and evaluated the precious figures on unfriendly outcomes in CKD patients of these 2 borders. When studied with the first day or evening quartile SBP, patients in the fourth quartile of the

evening SBP reported a substantial expansion in the probability of composite renal outcomes. In the light of these observations, SBP estimates at evening are indicated to be of greater benefit if composite renal outcomes and SBP estimates are expected in the day-to-day period.

REFERENCES:

1. Park JI, Baek H, Jung HH. Prevalence of chronic kidney disease in Korea: the Korean National Health and Nutritional Examination Survey 2011-2013. *J Korean Med Sci.* 2016;31:915–923. doi: 10.3346/jkms.2016.31.6.915. [[PMC](#) [free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. *J Am Coll Cardiol.* 2018;71:e127–e248. doi: 10.1161/HYP.0000000000000075. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
3. Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. *Adv Chronic Kidney Dis.* 2015;22:116–122. doi: 10.1053/j.ackd.2014.12.001. [[PMC](#) [free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
4. Appel LJ, Wright JT, Jr, Greene T, et al. AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med.* 2010;363:918–929. doi: 10.1056/NEJMoA0910975. [[PMC](#) [free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
5. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med.* 1994;330:877–884. doi: 10.1056/NEJM199403313301301. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
6. Ruggenenti P, Perna A, Loriga G, et al. REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet.* 2005;365:939–946. doi: 10.1016/S0140-6736(05)71082-5. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
7. Cheung AK, Rahman M, Reboussin DM, et al. SPRINT Research Group. Effects of intensive BP control in CKD. *J Am Soc Nephrol.* 2017;28:2812–2823. doi: 10.1681/ASN.2017020148. [[PMC](#) [free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
8. Pogue V, Rahman M, Lipkowitz M, et al. African American Study of Kidney Disease and Hypertension Collaborative Research Group. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. *Hypertension.* 2009;53:20–27. doi: 10.1161/HYPERTENSIONAHA.108.115154. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
9. Gorostidi M, Sarafidis PA, de la Sierra A, et al. Spanish ABPM Registry Investigators. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. *Am J Kidney Dis.* 2013;62:285–294. doi: 10.1053/j.ajkd.2013.03.025. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
10. Gustavsen PH, Høegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. *J Hum Hypertens.* 2003;17:811–817. doi: 10.1038/sj.jhh.1001643. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]